NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

This trial tests whether a drug that boosts NMDA receptor activity in the brain (a receptor involved in learning and memory) can improve cognitive problems — such as memory, attention, and thinking speed — in people with schizophrenia who are otherwise in remission from psychotic symptoms. **You may be eligible if...** - You have been diagnosed with schizophrenia and are currently in remission (low or no active psychotic symptoms for at least 6 months) - Your antipsychotic medication dose has been stable for at least 6 months - You are physically healthy with normal lab results - You are able to communicate effectively and complete study assessments **You may NOT be eligible if...** - You have intellectual disability or a substance use disorder - You have epilepsy, serious brain disease, or significant head trauma - You are pregnant or breastfeeding - You are taking clozapine Talk to your doctor to see if this trial is right for you.